


Tuesday, November 19, 2024

Management of Pulmonary Embolism : The Ultimate Team Sport

Michael R. Jaff, D.O.
Professor of Medicine (retired)
Harvard Medical School
Boston, Massachusetts
Chief Medical Officer
Boston Scientific Corporation




Michael R. Jaff, D.O. Conflicts of Interest

Part-Time Employee	Equity Shareholder	
Boston Scientific Corporation	Access Vascular	Nectero
Consultant	Boston Scientific	Primacea
Gilde Healthcare	Efemoral	Janacare
McKinsey	Emboltech	R3 Vascular
Vibrato Medical	Healthcare	Vascular Therapies
Board Member	HeartBeam	Venarum
Access Vascular, Inc		
HeartBeam		
Martha's Vineyard Hospital		

November 2024

Is There a Hotter Topic in Vascular/Endovascular Surgery Today than This?



We Have Brought Together the Best of the Best to Answer Key Questions....

- What's the fastest/most accurate diagnostic algorithm?
- Are DOACs all we need to use as medical therapy for PE?
- Do I need to screen for cancer/hypercoagulability in every PE?
- Is pharmacomechanical intervention the only way to manage PE?
- What are the ideal techniques to manage PE via intervention?
- Where does Surgery and ECMO fit into the management of PE?
- Is there a clear algorithm for the management of PE?
- When should an IVC Filter be placed?
- What's the story with BPA for CTEPH?
- Why have a PERT?

Here's a Clue for our PERT Today!!!!

- 73 y.o. female with obesity, prior non-obstructive CAD, chronic thrombocytopenia and anemia presenting with severe dyspnea
 - Progressive over last week
 - Intermittent chest pain
- Vitals:
 - BP: 98/52
 - HR: 120
 - RR: 22
 - O2: 82% on RA. Moved to 6L O2. 94%
- Respiratory distress. Accessory muscles. Tachycardic, regular.